The IgM antibody is used in the production of the firm’s cell therapy, which is scheduled to enter a Phase I study in 2009 for transverse myelitis.

Goodwin Biotechnology (GBI) has begun process development and will be manufacturing a mAb used by Q Therapeutics in purifying its cell therapy, Q-Cells™. The IgM antibody recognizes a unique cell-surface marker that is expressed on Q-Cells (neural glial cells).

Q Therapeutics will use the mAb to manufacture Q-Cells. The company anticipates beginning Phase I trials for the treatment of transverse myelitis, a rapidly paralyzing subset of multiple sclerosis, in 2009.

Previous articleA New Approach to Duchenne Muscular Dystrophy
Next articleResearchers Discover Effects of Continuous TNF Expression